2001
DOI: 10.1034/j.1600-051x.2001.028009848.x
|View full text |Cite
|
Sign up to set email alerts
|

Tacrolimus is not associated with gingival overgrowth in renal transplant patients

Abstract: This study demonstrates that tacrolimus has no adverse effects on the gingival tissues and thus has potential as an alternative immunosuppressant for individuals susceptible to developing cyclosporin A-induced gingival overgrowth.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

7
50
1
11

Year Published

2002
2002
2018
2018

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 45 publications
(70 citation statements)
references
References 18 publications
(28 reference statements)
7
50
1
11
Order By: Relevance
“…Based on the study of Shiboski et al,19 tacrolimus was not related to GO, and, similar to his findings, in our institution, none of the children who underwent liver transplantation who were treated with tacrolimus presented GO 13. Furthermore, neither James et al20 nor Greenberg et al21 found any association between the use of tacrolimus and GO in renal transplant patients. However, Cezário et al22 and Paixao et al23 related an association rate of 7.25% and 8.3%, respectively.…”
Section: Discussionsupporting
confidence: 81%
“…Based on the study of Shiboski et al,19 tacrolimus was not related to GO, and, similar to his findings, in our institution, none of the children who underwent liver transplantation who were treated with tacrolimus presented GO 13. Furthermore, neither James et al20 nor Greenberg et al21 found any association between the use of tacrolimus and GO in renal transplant patients. However, Cezário et al22 and Paixao et al23 related an association rate of 7.25% and 8.3%, respectively.…”
Section: Discussionsupporting
confidence: 81%
“…Esta paciente fue inicialmente tratada por un espacio de 6 años con CsA; debido al desarrollo de agrandamientos gingivales recurrentes, el equipo médico de trasplante decidió remplazar la CsA por Tcr, un inmunosupresor de nueva generación que ha demostrado ser exitoso para prevenir el rechazo de órganos trasplantados (20). Los resultados de los estudios que evalúan el desarrollo de agrandamiento gingival inducido por Tcr son controversiales (21) Greenberg y James reportan que Tcr no se asocia con el desarrollo de agrandamiento gingival (20,22). Otros autores han sugerido que el agrandamiento observado en sujetos que toman Tcr es menor que en aquellos que toman CsA y tiende a ser menos severo (23,24).…”
Section: Discussionunclassified
“…Adicionalmente, los pacientes receptores de trasplante renal frecuentemente desarrollan hipertensión arterial secundaria por lo que adjunto al tratamiento con inmunosupresores se utiliza terapia combinada con BCC (22), principalmente nifedipino y amlodipino. Medicación concomitante con BCC y CsA o Tcr ha mostrado un incremento en la prevalencia y severidad del agrandamiento gingival (23,26,27).…”
Section: Discussionunclassified
“…Hastanın hipertansiyonu kontrol altında değilse, operasyon sonrası oluşan hemoroji riski nedeniyle ertelenmelidir. 19,22,23 Ġlaca bağlı dişeti büyümelerin klinik ve histolojik görümü benzerdir. Bu büyümeler genellikle interdental papilladan başlar ve genellikle yapışık dişeti ile sınırlıdır.…”
Section: Discussionunclassified